ticlopidine has been researched along with Blood Loss, Surgical in 116 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Blood Loss, Surgical: Loss of blood during a surgical procedure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " the pharmacokinetics of clopidogrel do not allow for bleeding time to return to normal until the drug has been discontinued for five days." | 7.78 | Operative treatment of hip fractures in patients on clopidogrel: a case-control study. ( Chaput, CD; Patel, KV; Probe, RA; Wallace, HC, 2012) |
| "Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days." | 6.77 | Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012) |
| "Femoral neck fractures are an increasingly common injury in the elderly." | 5.37 | Femoral neck fractures in patients on Clopidogrel. The effect of delaying surgery and the introduction of the new SIGN guidelines. ( Cam, NB; Chambers, IR; Leonidou, A, 2011) |
| " Perioperative bleeding and composite of morbidity endpoints including myocardial infarction were compared in relation to the tertile distribution of the fibrinogen concentration." | 5.19 | Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery. ( Kim, EK; Kim, NY; Kwak, YL; Shim, JK; Song, JW, 2014) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| " As the indications for clopidogrel expand, an increasing number of patients undergoing off-pump coronary artery bypass surgery (OPCAB) are also undergoing dual antiplatelet therapy (DAPT), with its higher risk of bleeding complications." | 5.15 | Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery. ( Ahn, SW; Kwak, YL; Lee, JS; Shim, JK; Song, JW; Yoo, KJ, 2011) |
| "The patients at greatest risk, when discontinuing clopidogrel therapy, are those with drug eluting stents who may be at risk of stent thrombosis." | 4.87 | Clopidogrel dilemma for orthopaedic surgeons. ( Bell, G; Fletcher, JP; Fox, JS; Grigg, LE; Steele, MJ, 2011) |
| " the pharmacokinetics of clopidogrel do not allow for bleeding time to return to normal until the drug has been discontinued for five days." | 3.78 | Operative treatment of hip fractures in patients on clopidogrel: a case-control study. ( Chaput, CD; Patel, KV; Probe, RA; Wallace, HC, 2012) |
| "Dual antiplatelet therapy with combined aspirin and clopidogrel as well as clopidogrel is associated with an increased incidence of perioperative wound hematoma compared to aspirin but on an acceptable low level of incidence." | 3.78 | Risk of wound hematoma at carotid endarterectomy under dual antiplatelet therapy. ( Goertler, M; Halloul, Z; Heinze, HJ; Meyer, F; Oldag, A; Schreiber, S; Weber, M, 2012) |
| "An increasing number of patients suffering from cardiovascular disease, especially coronary artery disease (CAD), are treated with aspirin and/or clopidogrel for the prevention of major adverse events." | 3.77 | Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on ( Cattaneo, M; Chassot, PG; Eichinger, S; Hofmann, N; Huber, K; Korte, W; Rickli, H; Spannagl, M; Verheugt, F; von Heymann, C; Ziegler, B, 2011) |
| "Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days." | 2.77 | Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012) |
| "tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding." | 2.75 | Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010) |
| " Operating early on patients on clopidogrel is safe and does not appear to confer any clinically significant bleeding risk." | 2.53 | Clopidogrel and hip fractures, is it safe? A systematic review and meta-analysis. ( Della Torre, PK; Shatwell, MA; Soo, CG; Yolland, TJ, 2016) |
| "Postoperative complications were similar in the 2 groups." | 1.46 | Poor prognosis after surgery for intertrochanteric fracture in elderly patients with clopidogrel treatment: A cohort study. ( Chen, X; Liu, Z; Ren, J; Sun, T; Wang, J; Wang, X; Zhang, J, 2017) |
| " The purpose of this study was to compare the efficacy and safety of clopidogrel combined with aspirin (CA) versus sarpogrelate combined with aspirin (SA) treatment in carotid endarterectomy (CEA) patients." | 1.43 | Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study. ( Gu, Y; Guo, J; Guo, L; Qi, L; Tong, Z; Wang, Z; Yu, H; Zhang, J, 2016) |
| "Clopidogrel and ticlopidine, sometimes in combination with ASA, are associated with a low risk of bleeding during renal transplantation and does not seem to be a contraindication for renal transplant surgery." | 1.40 | Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study. ( Abramowicz, D; Benahmed, A; Broeders, N; Donckier, V; Ghisdal, L; Hoang, AD; Kianda, M; Le Moine, A; Lemy, A; Madhoun, P; Massart, A; Mikhalski, D; Racapé, J; Sadis, C; Wissing, M, 2014) |
| "Femoral neck fractures are an increasingly common injury in the elderly." | 1.37 | Femoral neck fractures in patients on Clopidogrel. The effect of delaying surgery and the introduction of the new SIGN guidelines. ( Cam, NB; Chambers, IR; Leonidou, A, 2011) |
| "Surgical blood loss was measured, and the groups were compared for statistically significant differences in blood loss." | 1.35 | The effect of platelet-altering medications on bleeding from minor oral surgery procedures. ( Alvarado, F; Campbell, JH; Partridge, CG, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.59) | 18.2507 |
| 2000's | 32 (27.59) | 29.6817 |
| 2010's | 81 (69.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Columbo, JA | 1 |
| Lambour, AJ | 1 |
| Sundling, RA | 1 |
| Chauhan, NB | 1 |
| Bessen, SY | 1 |
| Linshaw, DL | 1 |
| Kang, R | 1 |
| Riblet, NBV | 1 |
| Goodney, PP | 2 |
| Stone, DH | 2 |
| Buhatem Medeiros, F | 1 |
| Pepe Medeiros de Rezende, N | 1 |
| Bertoldi Franco, J | 1 |
| Porrio de Andrade, AC | 1 |
| Timerman, L | 1 |
| Gallottini, M | 1 |
| Itagiba Neves, IL | 1 |
| Ortega, KL | 1 |
| Zhang, J | 2 |
| Chen, X | 1 |
| Wang, J | 1 |
| Liu, Z | 1 |
| Wang, X | 1 |
| Ren, J | 1 |
| Sun, T | 1 |
| Pearcy, C | 1 |
| Almahmoud, K | 1 |
| Jackson, T | 1 |
| Hartline, C | 1 |
| Cahill, A | 1 |
| Spence, L | 1 |
| Kim, D | 1 |
| Olatubosun, O | 1 |
| Todd, SR | 1 |
| Campion, EM | 1 |
| Burlew, CC | 1 |
| Regner, J | 1 |
| Frazee, R | 1 |
| Michaels, D | 1 |
| Dissanaike, S | 1 |
| Stewart, C | 1 |
| Foley, N | 1 |
| Nelson, P | 1 |
| Agrawal, V | 1 |
| Truitt, MS | 1 |
| Prader, R | 1 |
| De Broca, B | 1 |
| Chevallier, D | 1 |
| Amiel, J | 1 |
| Durand, M | 1 |
| Shi, J | 2 |
| Ji, H | 2 |
| Ren, F | 1 |
| Wang, G | 2 |
| Xu, M | 1 |
| Xue, Y | 1 |
| Chen, M | 1 |
| Qi, J | 1 |
| Li, L | 2 |
| Faraday, N | 1 |
| Fujikawa, T | 1 |
| Noda, T | 1 |
| Tada, S | 1 |
| Tanaka, A | 1 |
| Wallace, HC | 1 |
| Probe, RA | 1 |
| Chaput, CD | 1 |
| Patel, KV | 1 |
| McKenzie, JL | 1 |
| Douglas, G | 1 |
| Bazargan, A | 1 |
| Fitchett, D | 1 |
| Mazer, CD | 1 |
| Eikelboom, J | 1 |
| Verma, S | 1 |
| Rouine-Rapp, K | 1 |
| McDermott, MW | 1 |
| Song, Y | 2 |
| Song, JW | 3 |
| Shim, JK | 5 |
| Kwak, YL | 5 |
| Al Khudairy, A | 1 |
| Al-Hadeedi, O | 1 |
| Sayana, MK | 1 |
| Galvin, R | 1 |
| Quinlan, JF | 1 |
| Girotra, C | 1 |
| Padhye, M | 1 |
| Mandlik, G | 1 |
| Dabir, A | 1 |
| Gite, M | 1 |
| Dhonnar, R | 1 |
| Pandhi, V | 1 |
| Vandekar, M | 1 |
| Abouzgheib, W | 1 |
| Meena, N | 1 |
| Jagtap, P | 1 |
| Schorr, C | 1 |
| Boujaoude, Z | 1 |
| Bartter, T | 1 |
| Benahmed, A | 1 |
| Kianda, M | 1 |
| Ghisdal, L | 1 |
| Broeders, N | 1 |
| Massart, A | 1 |
| Lemy, A | 1 |
| Mikhalski, D | 1 |
| Hoang, AD | 1 |
| Donckier, V | 1 |
| Sadis, C | 1 |
| Le Moine, A | 1 |
| Madhoun, P | 1 |
| Racapé, J | 1 |
| Wissing, M | 1 |
| Abramowicz, D | 1 |
| Zheng, Z | 1 |
| Liu, JH | 1 |
| Huang, FJ | 1 |
| Yu, JB | 1 |
| Kim, NY | 1 |
| Kim, EK | 1 |
| Capodanno, D | 1 |
| Anderson, K | 1 |
| Jupiter, DC | 1 |
| Abernathy, SW | 1 |
| Frazee, RC | 1 |
| Plicner, D | 1 |
| Mazur, P | 1 |
| Hymczak, H | 1 |
| Stoliński, J | 1 |
| Litwinowicz, R | 1 |
| Drwiła, R | 1 |
| Undas, A | 1 |
| Gielen, CL | 1 |
| Bruggemans, EF | 1 |
| Stijnen, T | 1 |
| Eikenboom, J | 1 |
| Tavilla, G | 1 |
| Brand, A | 1 |
| Klautz, RJ | 1 |
| Batchelder, A | 1 |
| Hunter, J | 1 |
| Cairns, V | 1 |
| Sandford, R | 1 |
| Munshi, A | 1 |
| Naylor, AR | 1 |
| Althaus, AB | 1 |
| Dovirak, O | 1 |
| Chang, P | 1 |
| Taylor, KN | 1 |
| O'Halloran, TD | 1 |
| Wagner, AA | 1 |
| Kuliczkowski, W | 1 |
| Sliwka, J | 1 |
| Kaczmarski, J | 1 |
| Zysko, D | 1 |
| Zembala, M | 2 |
| Steter, D | 1 |
| Fortmann, S | 1 |
| Serebruany, V | 1 |
| Hunter, JB | 1 |
| Carlson, ML | 1 |
| Sweeney, AD | 1 |
| Tombers, NM | 1 |
| Wanna, GB | 1 |
| Driscoll, CL | 1 |
| Haynes, DS | 1 |
| Lu, SY | 1 |
| Tsai, CY | 1 |
| Lin, LH | 1 |
| Lu, SN | 1 |
| Chu, EW | 2 |
| Chernoguz, A | 3 |
| Divino, CM | 4 |
| Soo, CG | 1 |
| Della Torre, PK | 1 |
| Yolland, TJ | 1 |
| Shatwell, MA | 1 |
| Guo, J | 1 |
| Gu, Y | 1 |
| Guo, L | 1 |
| Yu, H | 1 |
| Qi, L | 1 |
| Tong, Z | 1 |
| Wang, Z | 1 |
| Moon, K | 1 |
| Nanaszko, M | 1 |
| Levitt, MR | 1 |
| Gross, BA | 1 |
| Zabramski, JM | 1 |
| Spetzler, RF | 2 |
| Nakaji, P | 2 |
| Strosberg, DS | 1 |
| Corbey, T | 1 |
| Henry, JC | 1 |
| Starr, JE | 1 |
| Mattesi, L | 1 |
| Noailles, T | 1 |
| Rosencher, N | 1 |
| Rouvillain, JL | 1 |
| Jones, DW | 1 |
| Schermerhorn, ML | 1 |
| Brooke, BS | 1 |
| Conrad, MF | 1 |
| Wyers, MC | 1 |
| Ghanem, ES | 1 |
| Richard, RD | 1 |
| Wingert, NCH | 1 |
| Gotoff, JR | 1 |
| Graham, JH | 1 |
| Bowen, TR | 1 |
| Newsome, LT | 1 |
| Weller, RS | 1 |
| Gerancher, JC | 1 |
| Kutcher, MA | 1 |
| Royster, RL | 1 |
| Johansen, A | 1 |
| White, J | 1 |
| Turk, A | 1 |
| Ozao-Choy, J | 2 |
| Tammaro, Y | 2 |
| Fradis, M | 1 |
| Weber, K | 1 |
| Vaccarino, GN | 1 |
| Thierer, J | 1 |
| Albertal, M | 1 |
| Vrancic, M | 1 |
| Piccinini, F | 1 |
| Benzadón, M | 1 |
| Raich, H | 1 |
| Navia, DO | 1 |
| Jensen, MK | 1 |
| Hüttel, M | 1 |
| Kuczkowski, KM | 1 |
| Velik-Salchner, C | 1 |
| Maier, S | 1 |
| Innerhofer, P | 1 |
| Kolbitsch, C | 1 |
| Streif, W | 1 |
| Mittermayr, M | 1 |
| Praxmarer, M | 1 |
| Fries, D | 1 |
| Metzler, H | 1 |
| Prüller, F | 1 |
| Münch, A | 1 |
| Primus, G | 1 |
| Kainz, J | 1 |
| Hödl, R | 1 |
| Rehak, P | 1 |
| Duggan, ST | 1 |
| Keating, GM | 1 |
| Stewart, LC | 1 |
| Langtry, JA | 1 |
| Colombo, A | 1 |
| Gerber, RT | 1 |
| Savonitto, S | 1 |
| D'Urbano, M | 1 |
| Caracciolo, M | 1 |
| Barlocco, F | 1 |
| Mariani, G | 1 |
| Nichelatti, M | 1 |
| Klugmann, S | 1 |
| De Servi, S | 1 |
| Wait, SD | 1 |
| Abla, AA | 1 |
| Killory, BD | 1 |
| Starke, RM | 1 |
| García-Bracamonte, B | 1 |
| Vanaclocha, F | 1 |
| Johansen, M | 1 |
| Afshari, A | 1 |
| Kristensen, BB | 1 |
| Nydick, JA | 1 |
| Farrell, ED | 1 |
| Marcantonio, AJ | 1 |
| Hume, EL | 1 |
| Marburger, R | 1 |
| Ostrum, RF | 1 |
| Möllmann, H | 1 |
| Nef, HM | 1 |
| Hamm, CW | 1 |
| Wessely, R | 1 |
| Cerfolio, RJ | 1 |
| Minnich, DJ | 1 |
| Bryant, AS | 1 |
| Telem, DA | 2 |
| Llau, JV | 1 |
| Ferrandis, R | 1 |
| Sierra, P | 1 |
| Gómez-Luque, A | 1 |
| Kim, JC | 1 |
| Choi, YS | 2 |
| Yoo, KJ | 3 |
| Hussaini, BE | 1 |
| Thatte, HS | 1 |
| Rhodes, BA | 1 |
| Treanor, PR | 1 |
| Birjiniuk, V | 1 |
| Chechik, O | 2 |
| Thein, R | 1 |
| Fichman, G | 1 |
| Haim, A | 1 |
| Tov, TB | 1 |
| Steinberg, EL | 1 |
| Chu, E | 1 |
| Korte, W | 1 |
| Cattaneo, M | 1 |
| Chassot, PG | 2 |
| Eichinger, S | 1 |
| von Heymann, C | 1 |
| Hofmann, N | 1 |
| Rickli, H | 1 |
| Spannagl, M | 1 |
| Ziegler, B | 1 |
| Verheugt, F | 1 |
| Huber, K | 1 |
| Bracey, AW | 1 |
| Reyes, MA | 1 |
| Chen, AJ | 1 |
| Bayat, M | 1 |
| Allison, PM | 1 |
| Barequet, IS | 1 |
| Sachs, D | 1 |
| Shenkman, B | 1 |
| Priel, A | 1 |
| Wasserzug, Y | 1 |
| Budnik, I | 1 |
| Moisseiev, J | 1 |
| Salomon, O | 1 |
| Lee, JS | 1 |
| Ahn, SW | 1 |
| Duggie, AJ | 1 |
| Dimech, J | 1 |
| Zagórski, M | 1 |
| Goch, A | 1 |
| Nwachuku, IC | 1 |
| Jones, M | 1 |
| Clough, TM | 1 |
| Mariscalco, G | 1 |
| Bruno, VD | 1 |
| Cottini, M | 1 |
| Borsani, P | 1 |
| Banach, M | 1 |
| Piffaretti, G | 1 |
| Dominici, C | 1 |
| Beghi, C | 1 |
| Sala, A | 1 |
| Leonidou, A | 1 |
| Cam, NB | 1 |
| Chambers, IR | 1 |
| Douketis, JD | 1 |
| Edry, R | 1 |
| Katz, Y | 1 |
| Sylvester, DC | 1 |
| Coatesworth, AP | 1 |
| Bittner, HB | 1 |
| Lehmann, S | 1 |
| Rastan, A | 1 |
| Mohr, FW | 1 |
| Brizzio, ME | 1 |
| Shaw, RE | 1 |
| Bosticco, B | 1 |
| Collins, M | 1 |
| Grau, JB | 1 |
| Mak, AW | 1 |
| Zapolanski, A | 1 |
| Nathan, S | 1 |
| Steele, MJ | 1 |
| Fox, JS | 1 |
| Fletcher, JP | 2 |
| Grigg, LE | 1 |
| Bell, G | 1 |
| Thiele, T | 1 |
| Sümnig, A | 1 |
| Hron, G | 1 |
| Müller, C | 1 |
| Althaus, K | 1 |
| Schroeder, HW | 1 |
| Greinacher, A | 1 |
| Collinge, CA | 1 |
| Kelly, KC | 1 |
| Little, B | 1 |
| Weaver, T | 1 |
| Schuster, RD | 1 |
| Goldstein, Y | 1 |
| Behrbalk, E | 1 |
| Kaufman, E | 1 |
| Rabinovich, Y | 1 |
| Vetter, TR | 1 |
| Boudreaux, AM | 1 |
| Papapietro, SE | 1 |
| Smith, PW | 1 |
| Taylor, BB | 1 |
| Porterfield, JR | 1 |
| Smith, PK | 1 |
| Goodnough, LT | 1 |
| Levy, JH | 1 |
| Poston, RS | 1 |
| Short, MA | 1 |
| Weerakkody, GJ | 1 |
| Lenarz, LA | 1 |
| Oldag, A | 1 |
| Schreiber, S | 2 |
| Heinze, HJ | 1 |
| Meyer, F | 1 |
| Weber, M | 1 |
| Halloul, Z | 1 |
| Goertler, M | 1 |
| Radovanovic, I | 1 |
| Queally, J | 1 |
| Bahari, S | 1 |
| Sproule, J | 1 |
| McElwain, J | 1 |
| Price, MJ | 1 |
| Walder, JS | 1 |
| Baker, BA | 1 |
| Heiselman, DE | 1 |
| Jakubowski, JA | 1 |
| Logan, DK | 1 |
| Winters, KJ | 1 |
| Li, W | 1 |
| Angiolillo, DJ | 1 |
| Savage, JR | 1 |
| Parmar, A | 1 |
| Robinson, PJ | 1 |
| Lv, H | 1 |
| Yuan, S | 1 |
| Wang, Y | 1 |
| Paul, S | 1 |
| Stock, C | 1 |
| Chiu, YL | 1 |
| Kansler, A | 1 |
| Port, JL | 1 |
| Lee, PC | 1 |
| Stiles, BM | 1 |
| Nasar, A | 1 |
| Sedrakyan, A | 1 |
| Altorki, NK | 1 |
| Wordsworth, DR | 1 |
| Halsey, T | 1 |
| Griffiths, R | 1 |
| Parker, MJ | 1 |
| Feely, MA | 1 |
| Mabry, TM | 1 |
| Lohse, CM | 1 |
| Sems, SA | 1 |
| Mauck, KF | 1 |
| Akowuah, E | 1 |
| Shrivastava, V | 1 |
| Cooper, G | 1 |
| Pivalizza, EG | 1 |
| Warters, RD | 1 |
| Gottschalk, LI | 1 |
| Luehr, SL | 1 |
| Hartwell, EA | 1 |
| Schieber, M | 1 |
| Sechtem, U | 1 |
| Chu, MW | 1 |
| Wilson, SR | 1 |
| Novick, RJ | 1 |
| Stitt, LW | 1 |
| Quantz, MA | 1 |
| Kapetanakis, EI | 1 |
| Medlam, DA | 1 |
| Boyce, SW | 1 |
| Haile, E | 1 |
| Hill, PC | 1 |
| Dullum, MK | 1 |
| Bafi, AS | 1 |
| Petro, KR | 1 |
| Corso, PJ | 1 |
| Ascione, R | 1 |
| Ghosh, A | 1 |
| Rogers, CA | 1 |
| Cohen, A | 1 |
| Monk, C | 1 |
| Angelini, GD | 1 |
| Madi-Jebara, S | 1 |
| Rkeiby-Kassabian, N | 1 |
| Yazigi, A | 1 |
| Lindvall, G | 1 |
| Sartipy, U | 1 |
| van der Linden, J | 1 |
| Hitos, K | 1 |
| Purkayastha, S | 1 |
| Athanasiou, T | 1 |
| Malinovski, V | 1 |
| Tekkis, P | 1 |
| Foale, R | 1 |
| Casula, R | 1 |
| Glenville, B | 1 |
| Darzi, A | 1 |
| Hirose, H | 1 |
| Delabays, A | 1 |
| Ravussin, P | 1 |
| Spahn, DR | 1 |
| Oh, YJ | 1 |
| Bang, SO | 1 |
| Iwahashi, H | 1 |
| Tashiro, T | 1 |
| Morishige, N | 1 |
| Hayashida, Y | 1 |
| Ito, N | 1 |
| Takeuchi, K | 1 |
| Teshima, H | 1 |
| Kuwahara, G | 1 |
| Partridge, CG | 1 |
| Campbell, JH | 1 |
| Alvarado, F | 1 |
| Reichert, MG | 1 |
| Robinson, AH | 1 |
| Travis, JA | 1 |
| Hammon, JW | 1 |
| Kon, ND | 1 |
| Kincaid, EH | 1 |
| Benzimra, JD | 1 |
| Johnston, RL | 1 |
| Jaycock, P | 1 |
| Galloway, PH | 1 |
| Lambert, G | 1 |
| Chung, AK | 1 |
| Eke, T | 1 |
| Sparrow, JM | 1 |
| Price, J | 1 |
| Tadbiri, S | 1 |
| Pickard, AS | 1 |
| Becker, RC | 1 |
| Schumock, GT | 1 |
| Frye, CB | 1 |
| Rodin, IuV | 1 |
| Widimsky, P | 1 |
| Motovská, Z | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Pudil, R | 1 |
| Holm, F | 1 |
| Petr, R | 1 |
| Bílková, D | 1 |
| Skalická, H | 1 |
| Kuchynka, P | 1 |
| Poloczek, M | 1 |
| Miklík, R | 1 |
| Maly, M | 1 |
| Aschermann, M | 1 |
| Maltais, S | 1 |
| Perrault, LP | 1 |
| Do, QB | 1 |
| Alvarez, JM | 1 |
| Harper, RW | 1 |
| Peverill, RE | 1 |
| Aylward, P | 1 |
| Ley, SJ | 1 |
| Nevelsteen, A | 1 |
| Mortelmans, L | 1 |
| Van de Cruys, A | 1 |
| Merckx, E | 1 |
| Verhaeghe, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Antifibrinolytics on Bleeding and Transfusion Outcomes in Patients Receiving Coronary Artery Bypass Surgery With Preoperative Clopidogrel Exposure[NCT01060163] | 552 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study[NCT01960296] | Phase 2 | 48 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Alignment of Treatment Preferences and Repair Type for Veterans With AAA[NCT03115346] | 238 participants (Anticipated) | Interventional | 2017-04-15 | Active, not recruiting | |||
| Influence of Extracorporeal Circulation on Platelet Function of Patients Undergoing Cardiac Surgery - a Prospective Observational Study[NCT01354847] | 25 participants (Actual) | Observational | 2011-06-30 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Platelet Aggregometry to Drive the Surgical Timing in Elderlies With Hip Fracture and Receiving Clopidogrel.[NCT04642209] | 9 participants (Anticipated) | Observational | 2020-12-01 | Not yet recruiting | |||
| Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease[NCT01014624] | Phase 4 | 56 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
hematocrit levels change from preoperative to postoperative (NCT01960296)
Timeframe: baseline and Day 1
| Intervention | percent change (Mean) |
|---|---|
| Clopidogrel | -3 |
| Discontinue | -1 |
(NCT01960296)
Timeframe: up to 90 days
| Intervention | days (Mean) |
|---|---|
| Clopidogrel | 2.2 |
| Discontinue | 2.4 |
Perioperative Bleeding Complications as indicated by bleeding requiring re-admission. (NCT01960296)
Timeframe: up to 90 days post op
| Intervention | participants (Number) |
|---|---|
| Clopidogrel | 1 |
| Discontinue | 1 |
(NCT01960296)
Timeframe: up to 90 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel | 0 |
| Discontinue | 0 |
Development of perioperative bleeding complications as indicated for need for blood transfusions, hematoma, and bleeding requiring re-operation. (NCT01960296)
Timeframe: up to 90 days postop
| Intervention | participants (Number) |
|---|---|
| Clopidogrel | 0 |
| Discontinue | 0 |
(NCT01960296)
Timeframe: up to 90 days postop
| Intervention | mL (Mean) |
|---|---|
| Clopidogrel | 73.6 |
| Discontinue | 52.1 |
(NCT01960296)
Timeframe: Day 1
| Intervention | minutes (Mean) |
|---|---|
| Clopidogrel | 114.3 |
| Discontinue | 100.4 |
Number of patients discharged on the day of surgery (NCT01960296)
Timeframe: up to 90 days
| Intervention | participants (Number) | |
|---|---|---|
| same day discharged | hospital admission | |
| Clopidogrel | 8 | 13 |
| Discontinue | 12 | 10 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
Inhibition of platelet aggregation was assessed by Accumetrics VerifyNow® P2Y12 reaction units (PRU). On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. (NCT01014624)
Timeframe: Washout Day 1
| Intervention | percentage (Mean) |
|---|---|
| Prasugrel | 72.3 |
| Clopidogrel | 35.4 |
Time to return to baseline PRU (<= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to return to baseline PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to return to baseline PRU derived from: Number days to return to baseline PRU=-3.350+0.079*PI(1)+0.014*baseline PRU. The predicted number of days to return to baseline based on device-derived platelet percentage inhibition is reported for each treatment group. (NCT01014624)
Timeframe: up to 12 days after the last dose
| Intervention | days (Number) |
|---|---|
| Prasugrel | 6.2 |
| Clopidogrel | 3.7 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participants met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 3 | 5 | 6 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 3 | 5 | 7 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 5 | 5 | 6 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (<=) 20%. (NCT01014624)
Timeframe: up to 12 days after the last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 5 | 6 | 7 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of participants. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | cumulative percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| return to baseline PRU by washout day 1 | return to baseline PRU by washout day 3 | return to baseline PRU by washout day 5 | return to baseline PRU by washout day 6 | return to baseline PRU by washout day 7 | return to baseline PRU by washout day 9 | |
| Clopidogrel | 30.8 | 53.9 | 84.6 | 96.2 | 96.2 | 100.0 |
| Prasugrel | 0 | 3.6 | 37.0 | 62.9 | 77.8 | 100.0 |
On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | cumulative percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| returned to baseline PRU by washout day 1 | returned to baseline PRU by washout day 3 | returned to baseline PRU by washout day 5 | returned to baseline PRU by washout day 6 | returned to baseline PRU by washout day 7 | returned to baseline PRU by washout day 9 | |
| Clopidogrel | 30.8 | 53.9 | 80.8 | 88.5 | 96.2 | 100.0 |
| Prasugrel | 0.0 | 0.0 | 37.0 | 55.6 | 77.8 | 100.0 |
15 reviews available for ticlopidine and Blood Loss, Surgical
| Article | Year |
|---|---|
A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation | 2018 |
Perioperative management of anticoagulation in elective surgery.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Di | 2013 |
Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
Topics: Adenosine; Blood Loss, Surgical; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Dru | 2013 |
Clopidogrel and hip fractures, is it safe? A systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Chi-Square Distribution; Clopidogrel; Drug Administration Schedule; Femoral Ne | 2016 |
Discontinuation of Plavix
Topics: Blood Loss, Surgical; Clopidogrel; Hip Fractures; Humans; Platelet Aggregation Inhibitors; Postopera | 2016 |
Coronary artery stents: II. Perioperative considerations and management.
Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; | 2008 |
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidog | 2009 |
Clopidogrel: mechanisms of action and review of the evidence relating to use during skin surgery procedures.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Dermatologic Surgical Procedures; Drug Therapy, Combinat | 2010 |
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Dru | 2010 |
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Sten | 2010 |
Antiplatelet therapy in ENT surgery: a review.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Decision Making; Drug-Eluting Stents; Humans; Otorhinola | 2012 |
Clopidogrel dilemma for orthopaedic surgeons.
Topics: Attitude of Health Personnel; Blood Loss, Surgical; Clopidogrel; Decision Making; Dose-Response Rela | 2011 |
Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis.
Topics: Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Humans; Length of Stay | 2006 |
[Antiplatelet drugs and intraoperative hemorrhage].
Topics: Algorithms; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinati | 2006 |
Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting.
Topics: Blood Loss, Surgical; Blood Transfusion; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypa | 2008 |
20 trials available for ticlopidine and Blood Loss, Surgical
| Article | Year |
|---|---|
Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Clopidogr | 2013 |
Assessment of the risk of haemorrhage and its control following minor oral surgical procedures in patients on anti-platelet therapy: a prospective study.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Female; Hemostasis, Surgical; Humans; Male; | 2014 |
[Effects of preoperative uses of aspirin and clopidogrel on patients undergoing coronary artery bypass graft surgery].
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; | 2013 |
Impact of preoperative fibrinogen concentration on postoperative outcome in patients who received dual antiplatelet therapy in proximity to off-pump coronary bypass surgery.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Fibrinogen; Human | 2014 |
Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug Combinations; Female; Human | 2015 |
Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; D | 2015 |
The evaluation of clopidogrel use in perioperative general surgery patients: a prospective randomized controlled trial.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Elective Surgical Procedures; Female; General Surgery; Hosp | 2016 |
Carotid Endarterectomy on Antiplatelet Agents in the Era of Point-of-Care Testing.
Topics: Aged; Arizona; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Female; | 2016 |
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; C | 2010 |
Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery.
Topics: Aged; Blood Loss, Surgical; Blood Platelets; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, | 2010 |
Effect of hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Blood Coagulation; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2011 |
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Procedures; Clopidogrel; Fe | 2011 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Tranexamic Acid in on-pump coronary artery bypass grafting without clopidogrel and aspirin cessation: randomized trial and 1-year follow-up.
Topics: Antifibrinolytic Agents; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Coronar | 2013 |
Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting.
Topics: Aged; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Clopidogrel; Coronary Artery | 2005 |
Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery.
Topics: Aspirin; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Drug Administ | 2007 |
[Local hemostasis during the carotid endarterectomy under condition of antithrombocytic therapy].
Topics: Aged; Aprotinin; Blood Coagulation; Blood Loss, Surgical; Blood Volume; Carotid Stenosis; Clopidogre | 2007 |
Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Chronic Disease; Clopid | 2008 |
Effect of ticlopidine on blood loss, platelet turnover and platelet deposition on prosthetic surfaces in patients undergoing aorto-femoral bypass grafting.
Topics: Aorta; Blood Loss, Surgical; Blood Platelets; Blood Vessel Prosthesis; Double-Blind Method; Female; | 1991 |
81 other studies available for ticlopidine and Blood Loss, Surgical
| Article | Year |
|---|---|
Quantification of bleeding during dental extraction in patients on dual antiplatelet therapy.
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Dental Ca | 2017 |
Poor prognosis after surgery for intertrochanteric fracture in elderly patients with clopidogrel treatment: A cohort study.
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; China; Clopidogrel; Cohort S | 2017 |
Risky business? Investigating outcomes of patients undergoing urgent laparoscopic appendectomy on antithrombotic therapy.
Topics: Adult; Appendectomy; Appendicitis; Aspirin; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Fe | 2017 |
Outcome of Transurethral Resection of Bladder Tumor: Does Antiplatelet Therapy Really Matter? Analysis of a Retrospective Series.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carcinoma, Transitional Cell; Clopidogrel; C | 2017 |
Balancing thrombotic and bleeding risks related to antiplatelet therapy in coronary bypass surgery: Comment on "Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting".
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Female; Humans; | 2013 |
Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video).
Topics: Aged; Aspirin; Blood Loss, Surgical; Cholecystectomy; Coronary Artery Disease; Drug-Eluting Stents; | 2013 |
Operative treatment of hip fractures in patients on clopidogrel: a case-control study.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; Clopidogrel; | 2012 |
Perioperative management of a neurosurgical patient with a meningioma and recent coronary artery stent.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Coronary Artery Disease; Drug T | 2013 |
Optimal anticoagulation during off pump coronary artery bypass in patients recently exposed to clopidogrel.
Topics: Age Factors; Aged; Anastomosis, Surgical; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coro | 2013 |
Withholding clopidogrel for 3 to 6 versus 7 days or more before surgery in hip fracture patients.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Female; Hemorrhage; Hip Fractures; Human | 2013 |
Percutaneous dilational tracheostomy in patients receiving antiplatelet therapy: is it safe?
Topics: Aged; Blood Loss, Surgical; Case-Control Studies; Clopidogrel; Dilatation; Erythrocyte Indices; Fema | 2013 |
Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study.
Topics: Aspirin; Blood Loss, Surgical; Case-Control Studies; Clopidogrel; Dose-Response Relationship, Drug; | 2014 |
Preoperative fibrinogen and morbidity in patients with residual platelet inhibition undergoing off-pump coronary artery bypass grafting: cause or effect?
Topics: Blood Loss, Surgical; Coronary Artery Bypass, Off-Pump; Female; Fibrinogen; Humans; Male; Platelet A | 2014 |
Should clopidogrel be discontinued before laparoscopic cholecystectomy?
Topics: Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Cholecystectomy, Laparoscopic; Clopidogrel; Fe | 2014 |
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A | 2015 |
Aspirin and clopidogrel during robotic partial nephrectomy, is it safe?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Feasibility Studies; Fem | 2015 |
Predicting Bleeding Risk by Platelet Function Testing in Patients Undergoing Heart Surgery.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Aspirin; Blood Loss, Surgical; Cardiopulmonary Byp | 2015 |
Cochlear Implantation in the Setting of Perioperative Anticoagulation and Antiplatelet Therapy.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Cochlear Implantation; Female; Hem | 2016 |
Dental extraction without stopping single or dual antiplatelet therapy: results of a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Female; Humans; Male; Middle Aged; Pl | 2016 |
Effects of Sarpogrelate Combined with Aspirin in Patients Undergoing Carotid Endarterectomy in China: A Single-Center Retrospective Study.
Topics: Aged; Aspirin; Blood Loss, Surgical; Carotid Stenosis; China; Clopidogrel; Drug Therapy, Combination | 2016 |
Preoperative antiplatelet use does not increase incidence of bleeding after major operations.
Topics: Adult; Aged; Blood Loss, Surgical; Clopidogrel; Databases, Factual; Elective Surgical Procedures; Fe | 2016 |
Perioperative clopidogrel is associated with increased bleeding and blood transfusion at the time of lower extremity bypass.
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distribution; Clopidogrel; Databases, Fact | 2017 |
Preoperative Use of Clopidogrel Does Not Affect Outcomes for Femoral Neck Fractures Treated With Hemiarthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Cerebrovascular Disorders; Clopidogrel; Comorb | 2017 |
Clopidogrel therapy--implications for hip fracture surgery.
Topics: Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Drug Administration Schedule; Follow-Up Studie | 2008 |
Clopidogrel and bleeding after general surgery procedures.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Post | 2008 |
Impact of preoperative clopidogrel in off pump coronary artery bypass surgery: a propensity score analysis.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemostasis, Surgi | 2009 |
[Bleeding or stent thrombosis in combination with drug-eluting stents].
Topics: Aneurysm, False; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Drug-Eluting St | 2009 |
Clopidogrel and pregnancy: a situation pregnant with danger?
Topics: Adult; Blood Loss, Surgical; Clopidogrel; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy | 2009 |
An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study.
Topics: Aged; Anesthesia; Aspirin; Blood Loss, Surgical; Blood Platelets; Cardiopulmonary Bypass; Clopidogre | 2009 |
Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; Cell Adhe | 2010 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor | 2008 |
Safety of carotid endarterectomy while on clopidogrel (Plavix). Clinical article.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Edema; E | 2010 |
[Comment about patients with dual antiplatelet therapy].
Topics: Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Contraindications; Drug Therapy, Combina | 2010 |
The use of clopidogrel (Plavix) in patients undergoing nonelective orthopaedic surgery.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Contraindications; Femal | 2010 |
Clinical pharmacology: antiplatelet therapy during surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhibit | 2010 |
Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy resulting from urgent surgery.
Topics: Antithrombins; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; | 2011 |
General thoracic surgery is safe in patients taking clopidogrel (Plavix).
Topics: Adult; Aged; Aged, 80 and over; Alabama; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Case- | 2010 |
Assessing the risk of clopidogrel-related bleeding complications in patients undergoing inguinal herniorrhaphy.
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Critical Care; Female; Hematoma; Hernia, | 2011 |
Thromboresistant surfaces with low-dose anticoagulation alleviate clopidogrel-related complications in patients undergoing coronary artery bypass grafting.
Topics: Aged; Anticoagulants; Biocompatible Materials; Blood Loss, Surgical; Blood Transfusion; Boston; Ches | 2011 |
The effect of clopidogrel and aspirin on blood loss in hip fracture surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Drug Therapy | 2011 |
Cessation of clopidogrel before major abdominal procedures.
Topics: Abdomen; Aged; Analysis of Variance; Blood Loss, Surgical; Clopidogrel; Cohort Studies; Confidence I | 2011 |
Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on
Topics: Aspirin; Blood Loss, Surgical; Cardiovascular Surgical Procedures; Clopidogrel; Contraindications; C | 2011 |
How do we manage patients treated with antithrombotic therapy in the perioperative interval.
Topics: Anticoagulants; Antifibrinolytic Agents; Antithrombins; Aspirin; Blood Loss, Surgical; Blood Transfu | 2011 |
Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Drug Therapy, C | 2011 |
Emergency surgery following trancutaneous aortic valve insertion.
Topics: Aged, 80 and over; Aortic Valve; Aspirin; Blood Loss, Surgical; Clopidogrel; Emergency Medical Servi | 2011 |
[Application of activated eptacog alfa in cardiac surgery].
Topics: Adult; Aged; Blood Loss, Surgical; Cardiac Surgical Procedures; Clopidogrel; Factor VIIa; Female; Hu | 2011 |
Clopidogrel: is a surgical delay necessary in fractured neck of femur?
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Dipyridamole; Female; Femoral Neck Fract | 2011 |
Femoral neck fractures in patients on Clopidogrel. The effect of delaying surgery and the introduction of the new SIGN guidelines.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Clopidogrel; Female; Femoral Neck Fractures; Humans; | 2011 |
Perioperative management of patients receiving anticoagulant or antiplatelet therapy: a clinician-oriented and practical approach.
Topics: Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Evidence-Based Medicine; Humans; Periope | 2011 |
[Perioperative anti-platelet therapy management--protocol suggestion].
Topics: Aspirin; Blood Loss, Surgical; Clinical Protocols; Clopidogrel; Drug Therapy, Combination; Humans; P | 2011 |
Impact of clopidogrel on bleeding complications and survival in off-pump coronary artery bypass grafting.
Topics: Aged; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Restenosis; Dose | 2012 |
Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage.
Topics: Adenosine Diphosphate; Aged; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion; Clopi | 2012 |
Coronary artery bypass graft surgery in patients receiving antiplatelet therapy: can we "fine-tune" the balance of safety and efficacy?
Topics: Blood Coagulation Tests; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female | 2012 |
Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Clopidogrel; Drug Administration Schedule; D | 2012 |
The effects of clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Loss, Surgical; Clopidogrel; Cohort Studies; | 2012 |
Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Artery Diseases; Clopidogrel; Drug T | 2012 |
The perioperative management of patients with coronary artery stents: surveying the clinical stakeholders and arriving at a consensus regarding optimal care.
Topics: Adult; Advisory Committees; Alabama; Anesthesiology; Aspirin; Blood Loss, Surgical; Cardiac Catheter | 2012 |
Risk of wound hematoma at carotid endarterectomy under dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Drug Therapy, Combination; Endarterectomy, Carotid | 2012 |
Anticoagulant use and its effect on bleeding and complications in total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Clopidogrel; Elective S | 2012 |
Antiplatelet drugs in elective ENT surgery.
Topics: Aspirin; Blood Loss, Surgical; Clinical Protocols; Clopidogrel; Data Collection; Elective Surgical P | 2012 |
Management and outcomes of patients on preoperative plavix (clopidogrel) undergoing general thoracic surgery.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Clopidogr | 2013 |
Clopidogrel has no effect on mortality from hip fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2013 |
Safety of clopidogrel in hip fracture surgery.
Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Case-Control Studies; Clopidogrel; Cohort Studies; Fe | 2013 |
Coronary artery bypass graft surgery in patients with recent exposure to clopidogrel and aspirin therapy.
Topics: Aspirin; Blood Component Transfusion; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Hum | 2003 |
Clopidogrel and platelet transfusion in patients undergoing coronary artery bypass graft surgery.
Topics: Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; | 2003 |
[Must platelet aggregation inhibitors be discontinued before surgery?].
Topics: Angiography; Aspirin; Blood Loss, Surgical; Clopidogrel; Humans; Pacemaker, Artificial; Platelet Agg | 2004 |
Does clopidogrel increase blood loss following coronary artery bypass surgery?
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critica | 2004 |
Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Disease | 2005 |
In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution.
Topics: Aged; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Artery Bypass; Female; Heparin; Hospital | 2005 |
[Antiplatelet agents and regional anaesthesia: experience in 130 patients].
Topics: Aged; Aspirin; Autonomic Nerve Block; Blood Loss, Surgical; Blood Vessel Prosthesis Implantation; Cl | 2005 |
Venous thromboembolism and fractured neck of femur.
Topics: Aged; Aged, 80 and over; Anesthesia; Anticoagulants; Aspirin; Blood Loss, Surgical; Blood Transfusio | 2005 |
Clopidogrel (PLAVIX) increases risk of bleeding in a patient undergoing coronary artery bypass grafting.
Topics: Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Humans; Meta-Analysis | 2006 |
[Aprotinin reduces bleeding during off-pump coronary artery bypass grafting in a patient on ticlopidine; report of a case].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aprotinin; Blood Loss, Surgical; Coronary Ar | 2007 |
The effect of platelet-altering medications on bleeding from minor oral surgery procedures.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bl | 2008 |
Effects of a waiting period after clopidogrel treatment before performing coronary artery bypass grafting.
Topics: Academic Medical Centers; Blood Loss, Surgical; Blood Volume; Clopidogrel; Coronary Artery Bypass; D | 2008 |
The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications.
Topics: Aged; Anesthetics, Local; Anticoagulants; Aspirin; Blood Loss, Surgical; Cataract Extraction; Choroi | 2009 |
Aspirin and clopidogrel use in the perioperative period for non-cardiac surgery.
Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Drug-Eluting Stents; Humans; Intraoperative Complication | 2008 |
Effect of clopidogrel on bleeding and transfusions after off-pump coronary artery bypass graft surgery: impact of discontinuation prior to surgery.
Topics: Aged; Analysis of Variance; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery By | 2008 |
Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
Topics: Abciximab; Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Glycoprotein IIb/IIIa inhibitors, surgery and bleeding.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blood Loss, Surgical; Co | 1998 |
Quality care outcomes in cardiac surgery: the role of evidence-based practice.
Topics: Aged; Blood Loss, Surgical; California; Clopidogrel; Coronary Artery Bypass; Evidence-Based Medicine | 2001 |